Genocea Biosciences Gross Profit

The latest gross profit for GNCA is $270K as of March 2022. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Genocea Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, GNCA's gross profit moved from $0 to $270K. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genocea Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, GNCA currently prints $270K for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Genocea Biosciences's growth, margins, and balance sheet.

A gross profit figure of $270K for GNCA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting GNCA's gross profit ($270K), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.